Many scientists and researchers around the world are running a race against time to find the vaccine that ends the dreadful COVID-19 pandemic that has killed more than 600,000 people worldwide.
Pharmaceutical laboratories are working on different routes to supply coronavirus medications, and inhaling them is a widely used way to attack respiratory diseases. Medical society is relying on many of them to find a treatment against infection with the new COVID-19.
One of the countries that is working hard to find the solution to this terrible scourge is the United Kingdom, so British scientists have tested an inhaled medicine called SNG001 for now, which reduces the chances of developing severe coronavirus disease by 79% in patients who have received the drug, according to Synairgen , a biopharmaceutical specialized in viruses and lung biomarkers and who is the company that produces it.
It is a medicine that “greatly reduced the number of hospitalized patients with COVID-19 who progressed from ‘requiring oxygen’ to ‘requiring ventilation’,” the pharmacist emphasized, after testing it on 101 patients with the virus in nine hospitals in the United Kingdom, and reported that medicine significantly reduced difficulty breathing, one of the most common symptoms in severe conditions of this disease and that its active agent, inhaled beta interferon, has great potential to restore the immune response of the lung and makes the sick recover in an accelerated process.
According to Richard Marsden, CEO of the biopharmaceutical, SNG001 showed that patients who received it were “at least twice as likely to recover to the point that their daily activities were not compromised by being infected with SARS-CoV- two”.
It should be noted that scientists and researchers from the United Kingdom are also working, in a race against time, to develop a vaccine that stops the terrible coronavirus that is attacking the planet ruthlessly and ending the world economy.
The vaccine developed by the University of Oxford and the Astrazeneca laboratory was “safe” and “trains” the immune system, as revealed by the first phases of the study, made to more than a thousand healthy adult volunteers ranging from 18 to 55 years old, being so far one of the most promising projects, according to the results of the trial published in the medical journal The Lancet.